Citi initiated coverage of ResMed’s (RMD) U.S. shares with a Buy rating and $330 price target The firm believes the company’s gross margin expansion potential over the next few years is being underestimated in consensus estimates. Citi sees upside to ResMed’s fiscal 2027 estimates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: